Granzyme B is a member of the granzyme family of the serine proteases found specifically in the cytotoxic granules of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. They are synthesized, processed and released by exocytosis in lysosome-like granules containing perforin. Granzyme B has the strongest apoptotic activity of all the granzymes as a result of its caspase-like ability to cleave substrates at aspartic acid residues thereby activating procaspases directly and cleaving downstream caspase substrates. Recent studies have demonstrated that the expression of granzyme B by Immunohistochemistry in several entities of extranodal peripheral T cell lymphoma (PTCL) and NK cell lymphomas, including nasal and nasal-type NK/T cell lymphomas, hepatosplenic and non-hepatosplenic PTCL, enteropathy-type (ETCL) and non-ETCL intestinal PTCL, subcutaneous panniculitis-like PTCL (SPTCL), cutaneous CD8+ epidermotropic lymphomas as well as in nodal and cutaneous CD30+ anaplastic large cell lymphomas (ALCL). In contrast, only a few nodal PTCL-unspecified (UC) express cytotoxic phenotype while angioimmunoblastic (AILD) lymphomas do not. The expression of granzyme B may be important for the identification and classification of extranodal T- and NK-cell lymphomas since many of these tumors do not have specific morphology and phenotype.
6 mL (RTU), 10 mL (RTU), 1 mL(Conc.), 0.5 mL (Conc.), 200 tests – Xmatrx Elite, 50 tests – Xmatrx Elite, 5 slides – Xmatrx, 5 slides – Manual